Newbury Pharmaceuticals AB (NEWBRY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Newbury Pharmaceuticals AB (NEWBRY) has a cash flow conversion efficiency ratio of 0.072x as of February 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr2.26 Million ≈ $243.21K USD) by net assets (Skr31.30 Million ≈ $3.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See NEWBRY net asset quality index to measure how much of total assets are equity-financed.
Newbury Pharmaceuticals AB - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Newbury Pharmaceuticals AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Newbury Pharmaceuticals AB (NEWBRY) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Newbury Pharmaceuticals AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Newbury Pharmaceuticals AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chia Yi Steel Co Ltd
TWO:2067
|
-0.113x |
|
Chromocell Therapeutics Corporation
NYSE MKT:CHRO
|
0.069x |
|
Watta Holding Bhd
KLSE:7226
|
-0.009x |
|
Dharma Samudera Fishing Tbk
JK:DSFI
|
0.006x |
|
Trailbreaker Resources Ltd
V:TBK
|
-0.011x |
|
Unibap AB
ST:UNIBAP
|
-0.136x |
|
Auga Group AB
STU:W9Z
|
0.032x |
|
WISDOM ED.INTL.HLD.HD-01
F:5Q4
|
N/A |
Annual Cash Flow Conversion Efficiency for Newbury Pharmaceuticals AB (2021–2024)
The table below shows the annual cash flow conversion efficiency of Newbury Pharmaceuticals AB from 2021 to 2024. For the full company profile with market capitalisation and key ratios, see NEWBRY company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-08-31 | Skr51.92 Million ≈ $5.59 Million |
Skr-23.71 Million ≈ $-2.55 Million |
-0.457x | +2.92% |
| 2023-08-31 | Skr49.38 Million ≈ $5.31 Million |
Skr-23.23 Million ≈ $-2.50 Million |
-0.470x | -115.64% |
| 2022-08-31 | Skr68.77 Million ≈ $7.40 Million |
Skr-15.00 Million ≈ $-1.61 Million |
-0.218x | -106.38% |
| 2021-08-31 | Skr38.47 Million ≈ $4.14 Million |
Skr-4.07 Million ≈ $-437.57K |
-0.106x | -- |
About Newbury Pharmaceuticals AB
Newbury Pharmaceuticals AB (publ) operates as hybrid pharmaceutical company in Sweden and the Scandinavian market. It offers oncology, rare diseases, neurology, and other treatment products. Newbury Pharmaceuticals AB (publ) was incorporated in 2020 and is based in Lund, Sweden.